relapsed/refractory diffuse large B-cell lymphoma
diseaseOn this page
Summary
relapsed/refractory diffuse large B-cell lymphoma (MONDO:0000901) is a cancer and 18 clinical trials. Top therapeutic interventions include axicabtagene ciloleucel, glofitamab, and epcoritamab. A subtype of diffuse large B-cell lymphoma — broader associated-gene and molecular evidence is on the parent page (see Disease family below).
At a glance
- Classification: Cancer
- Clinical trials: 18
Clinical features
No curated clinical features (Orphanet) for this disease.
Identifiers
Disease identifiers
| Field | Value |
|---|---|
| Canonical name | relapsed/refractory diffuse large B-cell lymphoma |
| Mondo ID | MONDO:0000901 |
| DOID | DOID:0080192 |
| UMLS | C0855112 |
| MedGen | 208957 |
| GARD | 0022843 |
| Is cancer (heuristic) | yes |
Disease family
This is a subtype of diffuse large B-cell lymphoma. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.
Classification path: disease › human disease › disease by body system or component › immune system disorder › leukocyte disorder › B-cell neoplasm › neoplasm of mature B-cells › diffuse large B-cell lymphoma › relapsed/refractory diffuse large B-cell lymphoma
Related subtypes (29): breast diffuse large B-cell lymphoma, colorectal diffuse large B-cell lymphoma, gastric diffuse large B-cell lymphoma, liver diffuse large B-cell lymphoma, primary cutaneous diffuse large B-cell lymphoma, Leg type, primary pulmonary diffuse large B-cell lymphoma, small intestinal diffuse large B-cell lymphoma, splenic diffuse large B-cell lymphoma, thyroid gland diffuse large B-cell lymphoma, Epstein-Barr virus-positive diffuse large B-cell lymphoma of the elderly, plasmablastic lymphoma, diffuse large B-cell lymphoma of the central nervous system, T-cell/histiocyte rich large B cell lymphoma, diffuse large B-cell lymphoma with chronic inflammation, ALK-positive large B-cell lymphoma, primary effusion lymphoma, lymphomatoid granulomatosis, primary mediastinal large B-cell lymphoma, intravascular large B-cell lymphoma, high grade B-cell lymphoma, diffuse large B-cell lymphoma activated B-cell type, diffuse large B-cell lymphoma germinal center B-cell type, BN2 diffuse large B-cell lymphoma, EZB diffuse large B-cell lymphoma, MCD diffuse large B-cell lymphoma, N1 diffuse large B-cell lymphoma, ST2 diffuse large B-cell lymphoma, A53 diffuse large B-cell lymphoma, primary vitreoretinal large b-cell lymphoma
Genetics & variants
GWAS landscape
No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.
Variant details and genetic-evidence tiers
No tiered GWAS variants or ClinVar records for this disease.
Genes & proteins
No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).
Function
No pathway enrichment — requires an associated-gene cohort.
Therapeutics
No druggable-target or therapeutic data for this disease’s cohort.
Clinical trials & evidence
Clinical trials
Clinical trials: 18.
Phase distribution (across all retrieved trials)
| Phase | Trials |
|---|---|
| PHASE2 | 5 |
| PHASE1 | 5 |
| PHASE3 | 3 |
| PHASE2/PHASE3 | 2 |
| PHASE1/PHASE2 | 2 |
| Not specified | 1 |
Top trials by phase / activity
| NCT | Phase | Status | Title |
|---|---|---|---|
| NCT04442022 | PHASE2/PHASE3 | ACTIVE_NOT_RECRUITING | A Study of Rituximab-Gemcitabine-Dexamethasone-Platinum (R-GDP) With or Without Selinexor in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma |
| NCT06792253 | PHASE3 | RECRUITING | Study Comparing BEBT-908 Combined With R to SOC for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma |
| NCT07409428 | PHASE3 | RECRUITING | A Phase III Study of HMPL-760 Plus R-GemOx VS Placebo Plus R-GemOx in Relapsed/Refractory DLBCL |
| NCT03391466 | PHASE3 | COMPLETED | Study of Effectiveness of Axicabtagene Ciloleucel Compared to Standard of Care Therapy in Patients With Relapsed/Refractory Diffuse Large B Cell Lymphoma |
| NCT05664217 | PHASE2/PHASE3 | TERMINATED | NKTR-255 vs Placebo Following CD19-directed CAR-T Therapy in Patients With Relapsed/Refractory Large B-cell Lymphoma |
| NCT05335018 | PHASE2 | ACTIVE_NOT_RECRUITING | GPL in Patients with Relapsed/refractory Diffuse Large B Cell Lymphoma |
| NCT06601504 | PHASE2 | ACTIVE_NOT_RECRUITING | Study of HMPL-760 Plus R-GemOx Versus Placebo Plus R-GemOx in Relapsed/Refractory DLBCL |
| NCT06867536 | PHASE2 | RECRUITING | Hypofractionation Radiotherapy in Combination With Glofitamab in Relapsed/Refractory Diffuse B-cell Lymphoma With Baseline High Tumor Burden |
| NCT06902012 | PHASE1/PHASE2 | RECRUITING | Safety and Efficacy of Early Second Infusion of Axi-cel Based on ctDNA for R/R Large B - Cell Lymphoma |
| NCT07451652 | PHASE2 | RECRUITING | Low Dose Epcoritamab Plus GemOx in R/R DLBCL |
| NCT03287817 | PHASE1/PHASE2 | TERMINATED | Cluster of Differentiation Antigen 19/22(CD19/22) CAR T Cells (AUTO3) for the Treatment of Diffuse Large B Cell Lymphoma |
| NCT03992339 | PHASE2 | COMPLETED | A Study of Evaluating the Safety and Efficacy of ATG-010 in Relapsed/Refractory Diffuse Large B-Cell Lymphoma |
| NCT07424833 | PHASE1 | NOT_YET_RECRUITING | A Study of APG-3288 in Relapsed/Refractory Blood Cancers |
| NCT03886831 | PHASE1 | COMPLETED | A Study of PRT543 in Participants With Advanced Solid Tumors and Hematologic Malignancies |
| NCT04436107 | PHASE1 | COMPLETED | Zanubrutinib, in Combination With Lenalidomide, With or Without Rituximab in Participants With Relapsed/Refractory Diffuse Large B-Cell Lymphoma |
| NCT05354362 | PHASE1 | TERMINATED | A Study of ATG-010 in Combination With ATG-008 in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma |
| NCT06164327 | PHASE1 | UNKNOWN | Study of BEBT-908 Combined With Drugs in the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma |
| NCT03153462 | Not specified | APPROVED_FOR_MARKETING | Axicabtagene Ciloleucel Expanded Access Study |
Drugs tested across these trials (top 30)
| Molecule | Max phase | Trials referencing |
|---|---|---|
| AXICABTAGENE CILOLEUCEL | 4 | 2 |
| GLOFITAMAB | 4 | 2 |
| EPCORITAMAB | 4 | 1 |
| FLUDARABINE PHOSPHATE | 4 | 1 |
| GEMCITABINE | 4 | 1 |
| IFOSFAMIDE | 4 | 1 |
| FLUDARABINE | 3 | 1 |
| ONATASERTIB | 2 | 1 |
| POSELTINIB | 2 | 1 |
| CHEMBL290077 | 0 | 1 |
| CHEMBL5081624 | 0 | 1 |